• WKN: A2AR94
  • ISIN: NL0012044747
  • Land: Niederlande

Nachricht vom 30.04.2020 | 14:28

SHOP APOTHEKE EUROPE N.V.: Annual General Meeting approves all items on the agenda.

30.04.2020 / 14:28
The issuer is solely responsible for the content of this announcement.

SHOP APOTHEKE EUROPE N.V.: Annual General Meeting approves all items on the agenda.

Venlo, The Netherlands, 30 April 2020. Today's Annual General Meeting of SHOP APOTHEKE EUROPE N.V. approved all resolutions proposed by management by a large majority. A total of 52.87 percent of the share capital entitled to vote was represented. This corresponds to 7,118,453 shares. SHOP APOTHEKE EUROPE was actually among the first publicly listed companies in The Netherlands to successfully conduct a virtual Annual General Meeting.

As part of their presentation, the Management Board explained the key financial figures for the 2019 financial year and the outlook for the current 2020 financial year.

The resolutions included, among other things, the formal approval of the actions of the Management Board and the Supervisory Board as well as the re-appointment of MAZARS Accountants N.V. as auditors for the (consolidated) annual financial statements for 2020. Further, the Annual General Meeting also confirmed to name CFO-designate Jasper Eenhorst to the Management Board.

You can find further information about this year's Annual General Meeting in the Investor Relations section of our corporate website


SHOP APOTHEKE EUROPE is one of the leading and the fastest-growing online pharmacies in Continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its European market leadership. The product range for the whole family in the OTC, beauty and personal care products as well as prescription drugs segments is supplemented by high quality natural food and health products, low carb products and sports nutrition following the acquisition of nu3 GmbH in July 2018.

SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to 5 million active customers fast and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive pharmaceutical consulting services.

SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016 and is part of the SDAX index since 24 September 2018.

In addition to being traded on the Frankfurt stock exchange, SHOP APOTHEKE EUROPE'S convertible bonds (ISIN: DE000A19Y072) are also tradeable on the Dutch Euronext stock exchange, which operates the stock exchanges in Paris, Amsterdam, Brussels and Lisbon.
All published figures are preliminary and unaudited.



Trade and popular media:
Sven Schirmer
Tel: +49 221 99 53 44 31

Financial media:
Bettina Fries
Tel: +49 211 75 80 779

Investor relations:
Carmen Herkenrath
Tel.: +31 77 850 6109

Thomas Schnorrenberg
Tel.: +49 151 4653131

30.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.


Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.